Form 8-K - Current report:
SEC Accession No. 0001213900-25-046244
Filing Date
2025-05-21
Accepted
2025-05-21 09:17:38
Documents
13
Period of Report
2025-05-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242686-8k_unicycive.htm   iXBRL 8-K 25051
2 PRESS RELEASE DATED MAY 21, 2025 ea024268601ex99-1_unicycive.htm EX-99.1 4342
  Complete submission text file 0001213900-25-046244.txt   198119

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE uncy-20250521.xsd EX-101.SCH 3017
4 XBRL LABEL FILE uncy-20250521_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE uncy-20250521_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0242686-8k_unicycive_htm.xml XML 3787
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 25971061
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)